Business Daily Media

Men's Weekly

.

China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics

  • Written by ACN Newswire - Press Releases
HONG KONG, Jun 28, 2021 - (ACN Newswire) - 2021-6-23 / Gelonghui - China Biotech's cell therapy was approved by the NMPA to enter Phase I clinical trials as a Class I new drug, while the recent CAR-T cell therapy approval for product marketing in China means a new era of immune cell therapy has begun.
Source: official website of NMPA
image
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
China Biotech (8037.HK): Anticipating promising results from cell therapy and from precision diagnostics
According to

Read more //?#

Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion

Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...

Global Thryv voices bring a sharper lens to International Women’s Day

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...

AI curiosity fuels new wave of employee-led innovation in Australia

Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...

Is your search bar your competitor’s best salesperson?

A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...